论文部分内容阅读
目的探讨双路径先期化疗对Ⅲ期卵巢癌肿瘤细胞减灭术加术后化疗疗效和预后的影响。方法将36例Ⅲ期卵巢癌分为A、B两组,A组行双路径先期化疗加中间肿瘤细胞减灭术加术后化疗(22例);B组行初次肿瘤细胞减灭术加术后化疗(14例)。比较两组肿瘤细胞减灭术的彻底性、病情缓解率和生存率。结果A、B组达到理想肿瘤细胞减灭术者分别占86.4%和35.7%;手术时间分别为(190±20)m in和(270±30)m in;术中出血分别为(400±100)m l和(800±200)m l;病情缓解率分别为77.3%和35.7%;1,3年生存率分别为90.9%、64.3%和68.2%、35.7%(P<0.05),5年生存率分别为31.8%和21.4%(P>0.05)。结论双路径先期化疗用于Ⅲ期卵巢癌治疗,可以降低肿瘤细胞减灭术风险,提高理想肿瘤细胞减灭术比例和术后化疗反应率,对生存率有益。
Objective To investigate the effect of dual-path chemotherapy on the cytoreductive efficacy and prognosis of stage Ⅲ ovarian cancer after cytoreductive surgery and postoperative chemotherapy. Methods 36 cases of stage Ⅲ ovarian cancer were divided into two groups A and B, group A received dual-path chemotherapy plus intermediate cytoreductive surgery plus chemotherapy (n = 22); group B received initial cytoreductive surgery After chemotherapy (14 cases). The completeness of tumor cytoreduction, disease remission rate and survival rate were compared between the two groups. Results The patients who achieved the ideal tumor cytoreduction in group A and group B accounted for 86.4% and 35.7% respectively. The operative time was (190 ± 20) m in and (270 ± 30) m in respectively. The intraoperative bleeding were (400 ± 100) ), and (800 ± 200) ml respectively; The rates of remission were 77.3% and 35.7% respectively; The 1,3 and 3 year survival rates were 90.9%, 64.3% and 68.2%, 35.7% Respectively, 31.8% and 21.4% (P> 0.05). Conclusions Dual - pathways of advanced chemotherapy for stage Ⅲ ovarian cancer treatment can reduce the risk of cytoreductive surgery, improve the proportion of ideal tumor cytoreductive surgery and postoperative chemotherapy response rate, and have a good survival rate.